Aralez Pharma (ARLZ) Misses Q1 EPS by 48c

Aralez Pharma (NASDAQ: ARLZ) reported Q1 EPS of ($0.73), $0.48 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $8.06 million versus the consensus estimate of $9.7 million.

For earnings history and earnings-related data on Aralez Pharma (ARLZ) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Coty (COTY) Misses Q4 EPS by 1c, offers outlook
• Jaguar Health (JAGX) Tops Q2 EPS by 3647c